{"id":572,"date":"2020-02-17T11:21:50","date_gmt":"2020-02-17T10:21:50","guid":{"rendered":"https:\/\/www.sunrockbiopharma.com\/ccr9\/"},"modified":"2024-04-09T09:51:44","modified_gmt":"2024-04-09T07:51:44","slug":"ccr9","status":"publish","type":"page","link":"https:\/\/www.sunrockbiopharma.com\/es\/ccr9\/","title":{"rendered":"CCR9"},"content":{"rendered":"
[vc_row][vc_column css_animation=\u00bbfadeInUp\u00bb el_class=\u00bbbox-shadow\u00bb][vc_column_text]<\/p>\n
[\/vc_column_text][vc_column_text]Las citoquinas quimiot\u00e1cticas o quimioquinas se unen a receptores acoplados a prote\u00edna G y median m\u00faltiples funciones biol\u00f3gicas, entre ellas la adhesi\u00f3n y extravasaci\u00f3n de leucocitos. Existe una fuerte asociaci\u00f3n entre la expresi\u00f3n en c\u00e9lulas tumorales de ciertos receptores de quimioquinas y el progreso del c\u00e1ncer, desarrollo de met\u00e1stasis y mal pron\u00f3stico.<\/p>\n
El receptor de quimioquinas 9, CCR9, se expresa de forma natural en el timo y las criptas del intestino delgado.<\/p>\n
Se ha demostrado que la expresi\u00f3n de CCR9 se asocia con una recurrencia temprana y un aumento de la capacidad metast\u00e1tica en tumores s\u00f3lidos como c\u00e1ncer de p\u00e1ncreas y de ovario.<\/p>\n
Por otro lado, en tumores hematol\u00f3gicos como la leucemia linfobl\u00e1stica aguda de c\u00e9lulas T (T-ALL), CCR9 se encuentra sobreexpresado y se asocia con un aumento del potencial metast\u00e1sico y la quimiorresistencia de los tumores.[\/vc_column_text][\/vc_column][\/vc_row][vc_row foundry_padding=\u00bbpt0″][vc_column css_animation=\u00bbfadeInLeft\u00bb][vc_column_text]<\/p>\n
[\/vc_column_text][\/vc_column][vc_column css_animation=\u00bbfadeInUp\u00bb el_class=\u00bblista\u00bb][vc_column_text el_class=\u00bblista\u00bb]<\/p>\n
[\/vc_column_text][vc_column_text el_class=\u00bblista\u00bb]<\/p>\n
[\/vc_column_text][\/vc_column][\/vc_row][vc_row foundry_padding=\u00bbpt0 pb0″][vc_column css_animation=\u00bbfadeInLeft\u00bb][vc_column_text]<\/p>\n
[\/vc_column_text][\/vc_column][vc_column css_animation=\u00bbfadeInUp\u00bb][vc_column_text]<\/p>\n
SunRock, en colaboraci\u00f3n con CSIC, ha desarrollado anticuerpos novedosos anti-CCR9 que reconocen un ep\u00edtopo exclusivo y con actividad antitumoral mediada por ADCC y CDC. Estos anticuerpos han demostrado su eficacia y seguridad tanto en modelos in vitro<\/i> como in vivo<\/i>.<\/span><\/p>\n Los tumores de ratones tratados con anticuerpos anti-CCR9 mostraron un aumento de la apoptosis y la necrosis y una reducci\u00f3n de la angiog\u00e9nesis y la proliferaci\u00f3n celular (Chamorro et al. 2014; Somovilla-Crespo et al. 2018).<\/span><\/p>\n SunRock Biopharma posee los derechos globales y exclusivos de la propiedad intelectual que protege los anticuerpos dirigidos contra CCR9.<\/span><\/p>\n [\/vc_column_text][vc_tta_tour style=\u00bbflat\u00bb shape=\u00bbsquare\u00bb color=\u00bbwhite\u00bb active_section=\u00bb1″ el_class=\u00bbtour-anti\u00bb][vc_tta_section title=\u00bbSRB1″ tab_id=\u00bb1582107529302-90b36921-4902″][vc_column_text el_class=\u00bblista\u00bb]SRB1 es un anticuerpo anti-CCR9\u00a0first-in-class<\/em> que ha demostrado una elevada eficacia para tratar el c\u00e1ncer de p\u00e1ncreas y leucemia linfobl\u00e1stica aguda de c\u00e9lulas T en modelos precl\u00ednicos.<\/p>\n [\/vc_column_text][\/vc_tta_section][\/vc_tta_tour][\/vc_column][\/vc_row][vc_row css_animation=\u00bbfadeInUp\u00bb el_class=\u00bbfirst-section\u00bb][vc_column el_class=\u00bbbox-shadow\u00bb][vc_column_text]<\/p>\n [\/vc_column_text][vc_row_inner][vc_column_inner width=\u00bb1\/6″][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/6″][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=\u00bb1\/6″][vc_empty_space height=\u00bb65px\u00bb][vc_empty_space height=\u00bb20px\u00bb][vc_column_text]<\/p>\n [\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/6″][vc_column_text]<\/p>\n Descubrimiento<\/strong><\/p>\n [\/vc_column_text][vc_separator border_width=\u00bb4″][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Descubrimiento%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_empty_space height=\u00bb59px\u00bb][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4″ accent_color=\u00bb#45509a\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22in%20vitro%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb el_class=\u00bbem\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_column_text]<\/p>\n Precl\u00ednica<\/strong><\/p>\n [\/vc_column_text][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4″ accent_color=\u00bb#45509a\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22in%20vivo%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb el_class=\u00bbem\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_empty_space height=\u00bb59px\u00bb][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4″ accent_color=\u00bb#45509a\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Regulatoria%22%2C%22value%22%3A%2250%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_empty_space height=\u00bb59px\u00bb][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4″ accent_color=\u00bb#e0bf3d\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20I%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_column_text]<\/p>\n Fases cl\u00ednicas<\/strong><\/p>\n [\/vc_column_text][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4″ accent_color=\u00bb#e0bf3d\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20II%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_empty_space height=\u00bb59px\u00bb][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4″ accent_color=\u00bb#e0bf3d\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20III%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=\u00bb1\/6″][vc_column_text]<\/p>\n [\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/6″][vc_column_text el_class=\u00bbvisible-xs visible-sm\u00bb]Descubrimiento<\/strong>[\/vc_column_text][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Descubrimiento%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_column_text el_class=\u00bbvisible-xs visible-sm\u00bb]Precl\u00ednica<\/strong>[\/vc_column_text][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22in%20vitro%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb el_class=\u00bbem\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22in%20vivo%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb el_class=\u00bbem\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Regulatoria%22%2C%22value%22%3A%2250%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_column_text el_class=\u00bbvisible-xs visible-sm\u00bb]Fases cl\u00ednicas<\/strong>[\/vc_column_text][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20I%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20II%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom\u00bb width=\u00bb1\/12″][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20III%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":" [vc_row][vc_column css_animation=\u00bbfadeInUp\u00bb el_class=\u00bbbox-shadow\u00bb][vc_column_text] Diana CCR9 [\/vc_column_text][vc_column_text]Las citoquinas quimiot\u00e1cticas o quimioquinas se unen a receptores acoplados a prote\u00edna G y median m\u00faltiples…<\/p>\n","protected":false},"author":1,"featured_media":573,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mi_skip_tracking":false},"yoast_head":"\r\n\n
SRB1 ha demostrado eficacia in vivo<\/em>: c\u00e1ncer de p\u00e1ncreas<\/h4>\n
\n
\n
SRB1 ha demostrado eficacia in vivo<\/em>: modelo de c\u00e9lulas circulantes T-ALL<\/h4>\n
\n
Anti-CCR9 Pipeline<\/h2>\n
SRB1 (tumores hematol\u00f3gicos)<\/h5>\n
SRB1 (tumores s\u00f3lidos)<\/h5>\n